At 6 months of BEV treatment, 19 patients in the MGMT unmethylated group and 14 patients in the methylated group experienced tumor progression, with PFS of 26.9% and 54.8%, respectively (P<0.05). The gene discussed is MGMT; the disease is neoplasm.